LA
Lewis Asset Management, LLC
13F filer · CIK 0002004520Reported Jul 21, 2026
Net buyer this quarter
13F portfolio value$285MU.S. long equity reported on 13F
Positions15220 new · 7 closed
Net flow last quarter+$8.29MBuys minus sells
Top 10 positions weight30.9%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Jul 21, 2026152 positions | |||||
| $16.6M | 5.82% | 0.00% | -2.8% | Q4 2023 | |
| $16M | 5.62% | 0.00% | +0.2% | Q4 2023 | |
| $12.4M | 4.35% | Not reported | +0.6% | Q2 2025 | |
| $9.1M | 3.19% | 0.00% | +0.9% | Q4 2023 | |
| $6.93M | 2.43% | 0.00% | -2.8% | Q4 2023 | |
| $6.2M | 2.17% | Not reported | -1.0% | Q4 2023 | |
| $5.54M | 1.94% | 0.00% | +3.1% | Q4 2023 | |
| $5.38M | 1.88% | 0.00% | -0.5% | Q4 2023 | |
| $5.32M | 1.86% | Not reported | +1.5% | Q4 2023 | |
| $4.78M | 1.68% | 0.00% | -7.1% | Q4 2023 | |
| $4.45M | 1.56% | Not reported | Not reported | Q2 2025 | |
| $4.08M | 1.43% | 0.00% | +19.2% | Q4 2023 | |
| $3.99M | 1.40% | 0.03% | +6.6% | Q3 2024 | |
| $3.99M | 1.40% | Not reported | -2.9% | Q4 2023 | |
| $3.74M | 1.31% | 0.00% | +0.2% | Q4 2023 | |
| $3.74M | 1.31% | 0.00% | -16.2% | Q4 2023 | |
| $3.2M | 1.12% | 0.00% | -0.4% | Q4 2023 | |
| $3.19M | 1.12% | 0.00% | +2.7% | Q4 2023 | |
| $3.17M | 1.11% | 0.00% | +3.7% | Q4 2023 | |
| $3.08M | 1.08% | 0.00% | +14.2% | Q2 2024 | |
| $2.94M | 1.03% | Not reported | +4.3% | Q4 2023 | |
| $2.79M | 0.98% | 0.00% | +209.5% | Q1 2026 | |
| $2.79M | 0.98% | 0.00% | +0.4% | Q4 2023 | |
| $2.61M | 0.91% | 0.06% | +4.2% | Q1 2024 | |
| $2.58M | 0.91% | Not reported | Not reported | Q4 2023 | |
| $2.55M | 0.89% | 0.00% | +3.0% | Q4 2023 | |
| $2.21M | 0.78% | 0.00% | +3.7% | Q4 2023 | |
| $2.1M | 0.73% | 0.00% | +4.2% | Q4 2023 | |
| $1.87M | 0.65% | 0.00% | New | Q2 2026 | |
| $1.82M | 0.64% | 0.00% | +11.6% | Q4 2023 | |
| $1.81M | 0.63% | 0.00% | -2.9% | Q4 2023 | |
| $1.68M | 0.59% | 0.00% | -6.8% | Q4 2023 | |
| $1.67M | 0.58% | 0.00% | -6.9% | Q2 2025 | |
| $1.66M | 0.58% | 0.00% | +8.6% | Q4 2023 | |
| $1.65M | 0.58% | 0.03% | -24.0% | Q4 2023 | |
| $1.61M | 0.56% | 0.00% | +1.7% | Q4 2023 | |
| $1.6M | 0.56% | 0.00% | +376.3% | Q4 2023 | |
| $1.54M | 0.54% | 0.00% | +0.2% | Q4 2023 | |
| $1.54M | 0.54% | 0.00% | -1.8% | Q2 2025 | |
| $1.45M | 0.51% | 0.00% | -3.9% | Q4 2023 | |
| $1.42M | 0.50% | 0.00% | +0.7% | Q4 2023 | |
| $1.36M | 0.48% | 0.00% | +0.7% | Q1 2024 | |
| $1.36M | 0.48% | 0.00% | +29.4% | Q4 2023 | |
| $1.32M | 0.46% | 0.00% | +7.7% | Q4 2023 | |
| $1.31M | 0.46% | 0.00% | +1.2% | Q2 2025 | |
| $1.31M | 0.46% | 0.00% | +6.1% | Q4 2023 | |
| $1.27M | 0.44% | 0.00% | +16.2% | Q2 2025 | |
| $1.26M | 0.44% | 0.00% | Not reported | Q4 2023 | |
| $1.2M | 0.42% | 0.00% | -3.4% | Q4 2024 | |
| $1.16M | 0.41% | 0.00% | +1.3% | Q4 2024 | |
| Q1 2026Reported Apr 21, 2026138 positions | |||||
| $14.9M | 6.09% | 0.00% | -10.2% | Q4 2023 | |
| $14M | 5.74% | 0.00% | -0.4% | Q4 2023 | |
| $10.7M | 4.39% | Not reported | +0.6% | Q2 2025 | |
| $7.87M | 3.22% | 0.00% | +9.7% | Q4 2023 | |
| $5.74M | 2.34% | 0.00% | -0.5% | Q4 2023 | |
| $5.34M | 2.18% | 0.00% | +0.9% | Q4 2023 | |
| $5.33M | 2.18% | Not reported | +3.5% | Q4 2023 | |
| $5.08M | 2.08% | Not reported | -7.0% | Q4 2023 | |
| $4.43M | 1.81% | 0.00% | +1.8% | Q4 2023 | |
| $4.21M | 1.72% | 0.03% | +18.6% | Q3 2024 | |
| $3.95M | 1.61% | Not reported | +0.4% | Q2 2025 | |
| $3.93M | 1.61% | Not reported | -2.9% | Q4 2023 | |
| $3.6M | 1.47% | 0.00% | -3.3% | Q4 2023 | |
| $3.35M | 1.37% | 0.00% | +0.2% | Q4 2023 | |
| $3.31M | 1.35% | 0.00% | +0.4% | Q4 2023 | |
| $2.96M | 1.21% | 0.00% | +16.0% | Q4 2023 | |
| $2.79M | 1.14% | 0.00% | -0.2% | Q4 2023 | |
| $2.51M | 1.03% | 0.00% | +1.4% | Q4 2023 | |
| $2.47M | 1.01% | 0.00% | +25.2% | Q4 2023 | |
| $2.28M | 0.93% | 0.00% | +24.2% | Q4 2023 | |
| $2.27M | 0.93% | Not reported | -0.2% | Q4 2023 | |
| $2.21M | 0.90% | Not reported | -3.1% | Q4 2023 | |
| $2.19M | 0.90% | 0.04% | +1.7% | Q4 2023 | |
| $2.1M | 0.86% | 0.00% | +1.5% | Q4 2023 | |
| $2.09M | 0.85% | 0.06% | +3.6% | Q1 2024 | |
| $2.07M | 0.85% | 0.00% | +0.3% | Q4 2023 | |
| $1.97M | 0.80% | 0.00% | +6.0% | Q4 2023 | |
| $1.8M | 0.74% | 0.00% | -4.0% | Q4 2023 | |
| $1.8M | 0.74% | 0.00% | 0.0% | Q2 2025 | |
| $1.79M | 0.73% | 0.00% | -28.0% | Q4 2023 | |
| $1.78M | 0.73% | 0.00% | +5.9% | Q2 2024 | |
| $1.73M | 0.71% | 0.00% | +0.1% | Q4 2023 | |
| $1.46M | 0.60% | 0.00% | +2.6% | Q4 2023 | |
| $1.44M | 0.59% | 0.00% | +10.2% | Q4 2023 | |
| $1.39M | 0.57% | 0.00% | +3.8% | Q3 2024 | |
| $1.32M | 0.54% | 0.00% | Not reported | Q2 2025 | |
| $1.27M | 0.52% | 0.00% | +4.4% | Q1 2024 | |
| $1.26M | 0.52% | 0.00% | +3.0% | Q4 2024 | |
| $1.24M | 0.51% | 0.00% | +2.5% | Q4 2023 | |
| $1.19M | 0.49% | 0.00% | +5.5% | Q4 2023 | |
| $1.18M | 0.48% | 0.00% | +12.8% | Q4 2023 | |
| $1.11M | 0.45% | 0.00% | +1.7% | Q4 2023 | |
| $1.05M | 0.43% | 0.00% | +3.1% | Q4 2024 | |
| $1M | 0.41% | 0.00% | +1.4% | Q4 2023 | |
| $970K | 0.40% | 0.00% | -1.2% | Q4 2023 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $950K | 0.39% | 0.02% | +0.2% | Q2 2024 |
| $940K | 0.38% | 0.00% | -1.4% | Q4 2023 | |
| $926K | 0.38% | 0.00% | New | Q1 2026 | |
| $914K | 0.37% | 0.00% | +0.5% | Q4 2023 | |
| $900K | 0.37% | 0.00% | Not reported | Q2 2025 | |
| Q4 2025Reported Jan 15, 2026136 positions | |||||
| $17.7M | 7.23% | 0.00% | -10.4% | Q4 2023 | |
| $15.1M | 6.15% | 0.00% | -2.6% | Q4 2023 | |
| $11.2M | 4.56% | Not reported | -0.5% | Q2 2025 | |
| $7.96M | 3.24% | 0.00% | -9.4% | Q4 2023 | |
| $6.91M | 2.81% | 0.00% | -7.9% | Q4 2023 | |
| $6.27M | 2.55% | 0.00% | +2.2% | Q4 2023 | |
| $5.98M | 2.43% | Not reported | -3.0% | Q4 2023 | |
| $5.94M | 2.42% | Not reported | +3.2% | Q4 2023 | |
| $4.87M | 1.98% | 0.00% | +2.7% | Q4 2023 | |
| $4.25M | 1.73% | Not reported | +0.1% | Q4 2023 | |
| $4.08M | 1.66% | Not reported | +0.8% | Q2 2025 | |
| $3.7M | 1.51% | 0.00% | -3.2% | Q4 2023 | |
| $3.53M | 1.44% | 0.03% | +13.9% | Q3 2024 | |
| $3.15M | 1.28% | 0.00% | +1.5% | Q4 2023 | |
| $3M | 1.22% | 0.00% | +1.5% | Q4 2023 | |
| $2.85M | 1.16% | 0.00% | -0.1% | Q4 2023 | |
| $2.68M | 1.09% | 0.00% | -2.3% | Q4 2023 | |
| $2.48M | 1.01% | 0.04% | +5.1% | Q4 2023 | |
| $2.43M | 0.99% | Not reported | -6.7% | Q4 2023 | |
| $2.3M | 0.94% | 0.00% | -12.2% | Q4 2023 | |
| $2.22M | 0.90% | Not reported | +0.5% | Q4 2023 | |
| $2.21M | 0.90% | 0.00% | +0.2% | Q4 2023 | |
| $2.18M | 0.89% | 0.05% | +10.7% | Q1 2024 | |
| $2.14M | 0.87% | 0.00% | -1.2% | Q4 2023 | |
| $2.11M | 0.86% | 0.00% | +1.5% | Q4 2023 | |
| $2.06M | 0.84% | 0.00% | +13.4% | Q4 2023 | |
| $1.98M | 0.81% | 0.00% | -9.3% | Q4 2023 | |
| $1.83M | 0.74% | 0.00% | +1.3% | Q4 2023 | |
| $1.77M | 0.72% | 0.00% | -0.1% | Q2 2025 | |
| $1.7M | 0.69% | 0.00% | +127.4% | Q4 2023 | |
| $1.67M | 0.68% | 0.00% | +0.7% | Q2 2024 | |
| $1.56M | 0.63% | 0.02% | +3.8% | Q1 2025 | |
| $1.52M | 0.62% | 0.00% | +1.0% | Q3 2024 | |
| $1.51M | 0.62% | 0.00% | +0.5% | Q4 2023 | |
| $1.47M | 0.60% | 0.00% | -5.6% | Q4 2023 | |
| $1.47M | 0.60% | 0.00% | -2.9% | Q4 2023 | |
| $1.44M | 0.59% | 0.00% | +0.8% | Q4 2023 | |
| $1.32M | 0.54% | 0.00% | +2.1% | Q4 2023 | |
| $1.27M | 0.52% | 0.00% | -6.2% | Q4 2023 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $1.22M | 0.49% | 0.03% | -12.0% | Q2 2024 |
| $1.19M | 0.49% | 0.00% | +4.0% | Q4 2023 | |
| $1.17M | 0.48% | 0.00% | -0.5% | Q4 2024 | |
| $1.16M | 0.47% | 0.00% | -6.5% | Q4 2023 | |
| $1.12M | 0.45% | 0.00% | +0.6% | Q1 2024 | |
| $1.1M | 0.45% | 0.00% | Not reported | Q2 2025 | |
| $1.05M | 0.43% | 0.00% | +3.3% | Q4 2023 | |
| $999K | 0.41% | 0.00% | -9.8% | Q4 2023 | |
| $993K | 0.40% | 0.00% | -8.6% | Q4 2023 | |
| $985K | 0.40% | 0.00% | +5.9% | Q4 2024 | |
| $967K | 0.39% | 0.00% | +2.1% | Q4 2023 | |
| Q3 2025Reported Oct 20, 2025138 positions | |||||
| $19.8M | 8.14% | 0.00% | -7.0% | Q4 2023 | |
| $14.5M | 5.97% | 0.00% | +9.5% | Q4 2023 | |
| $11M | 4.52% | Not reported | +28.8% | Q2 2025 | |
| $8.35M | 3.43% | 0.00% | +5.5% | Q4 2023 | |
| $8.04M | 3.30% | 0.00% | +9.7% | Q4 2023 | |
| $6.4M | 2.63% | Not reported | -0.6% | Q4 2023 | |
| $5.52M | 2.27% | 0.00% | +1.1% | Q4 2023 | |
| $4.78M | 1.97% | Not reported | +7.7% | Q4 2023 | |
| $4.77M | 1.96% | 0.00% | +6.8% | Q4 2023 | |
| $4.52M | 1.86% | 0.00% | +1.0% | Q4 2023 | |
| $4.24M | 1.74% | Not reported | +4.0% | Q4 2023 | |
| $3.9M | 1.60% | Not reported | +3.3% | Q2 2025 | |
| $3.06M | 1.26% | 0.00% | +17.2% | Q4 2023 | |
| $3.06M | 1.26% | 0.02% | +26.1% | Q3 2024 | |
| $2.78M | 1.14% | 0.00% | +7.3% | Q4 2023 | |
| $2.77M | 1.14% | 0.00% | +0.6% | Q4 2023 | |
| $2.73M | 1.12% | 0.00% | +3.4% | Q4 2023 | |
| $2.54M | 1.04% | Not reported | +23.2% | Q4 2023 | |
| $2.46M | 1.01% | 0.04% | 0.0% | Q4 2023 | |
| $2.31M | 0.95% | 0.00% | -16.5% | Q4 2023 | |
| $2.23M | 0.92% | 0.00% | +4.1% | Q4 2023 | |
| $2.18M | 0.90% | Not reported | +14.8% | Q4 2023 | |
| $1.97M | 0.81% | 0.00% | +0.9% | Q4 2023 | |
| $1.94M | 0.80% | 0.00% | +11.1% | Q4 2023 | |
| $1.86M | 0.76% | 0.00% | +6.1% | Q4 2023 | |
| $1.84M | 0.76% | 0.00% | +16.6% | Q4 2023 | |
| $1.81M | 0.74% | 0.00% | +0.1% | Q3 2024 | |
| $1.76M | 0.72% | 0.00% | +19.6% | Q2 2025 | |
| $1.65M | 0.68% | 0.00% | -0.4% | Q4 2023 | |
| $1.5M | 0.62% | 0.00% | +8.5% | Q4 2023 | |
| $1.49M | 0.61% | 0.00% | +2.1% | Q4 2023 | |
| $1.47M | 0.60% | 0.00% | +7.8% | Q2 2024 | |
| $1.47M | 0.60% | 0.05% | +26.9% | Q1 2024 | |
| $1.46M | 0.60% | 0.00% | +4.9% | Q4 2023 | |
| $1.42M | 0.58% | 0.00% | +99.3% | Q4 2023 | |
| $1.39M | 0.57% | 0.00% | -2.1% | Q4 2023 | |
| $1.38M | 0.57% | 0.01% | +36.6% | Q1 2025 | |
| $1.26M | 0.52% | 0.00% | +11.1% | Q4 2023 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $1.24M | 0.51% | 0.03% | +61.3% | Q2 2024 |
| $1.21M | 0.50% | 0.00% | +4.3% | Q4 2023 | |
| $1.12M | 0.46% | 0.00% | +24.4% | Q4 2023 | |
| $1.12M | 0.46% | 0.00% | -2.8% | Q4 2023 | |
| $1.1M | 0.45% | 0.00% | -1.6% | Q4 2023 | |
| $1.07M | 0.44% | 0.00% | +1.3% | Q4 2024 | |
| $1.07M | 0.44% | 0.00% | +2.8% | Q4 2023 | |
| $1.05M | 0.43% | 0.00% | +15.6% | Q1 2024 | |
| $1.05M | 0.43% | 0.00% | +3.0% | Q4 2023 | |
| $1.04M | 0.43% | Not reported | -1.0% | Q4 2023 | |
| $980K | 0.40% | 0.00% | +1.5% | Q4 2023 | |
| $940K | 0.39% | 0.00% | +1.6% | Q4 2024 | |
Premium opens every quarter this fund has filed